{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:19:02Z","timestamp":1793053142274,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:00:00Z","timestamp":1657324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["105827, 106619, 107247, 108047, and 107159"],"award-info":[{"award-number":["105827, 106619, 107247, 108047, and 107159"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A considerable proportion of cervical cancer diagnoses in high-income countries are due to lack of timely follow-up of an abnormal screening result. We estimated colposcopy non-attendance, examined the potential factors associated and described non-attendance reasons in a population-based screening study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the MARZY prospective cohort study were analysed. Co-test screen-positive women (atypical squamous cells of undetermined significance or worse [ASC-US+] or high-risk human papillomavirus [hrHPV] positive) aged 30 to 65\u00a0years were referred to colposcopy within two screening rounds (3-year interval). Women were surveyed for sociodemographic, HPV-related and other data, and interviewed for non-attendance reasons. Logistic regression was used to examine potential associations with colposcopy attendance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 2,627 women were screened (screen-positive\u2009=\u20098.7%), and 2,093 again at follow-up (screen-positive\u2009=\u20095.1%; median 2.7\u00a0years later). All screen-positives were referred to colposcopy, however 28.9% did not attend despite active recall. Among co-test positives (ASC-US+\u2009and hrHPV) and only hrHPV positives, 19.6% were non-attendees. Half of only ASC-US+\u2009screenees attended colposcopy. Middle age (adjusted odds ratio [aOR]\u2009=\u20091.55, 95% CI 1.02, 4.96) and hrHPV positive result (aOR\u2009=\u20093.04, 95% CI 1.49, 7.22) were associated with attendance. Non-attendance was associated with having\u2009\u2265\u20093 children (aOR\u2009=\u20090.32, 95% CI 0.10, 0.86). Major reasons for non-attendance were lack of time, barriers such as travel time, need for childcare arrangements and the advice against colposcopy given by the gynaecologist who conducted screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Follow-up rates of abnormal screening results needs improvement. A systematic recall system integrating enhanced communication and addressing follow-up barriers may improve screening effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-022-01851-6","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T07:02:54Z","timestamp":1657350174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Linda A.","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke R.","family":"Zeissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Schauberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Merzweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Radde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Fischbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Ikenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Blettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie J.","family":"Klug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,9]]},"reference":[{"issue":"5","key":"1851_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","volume":"26","author":"PJ Maver","year":"2020","unstructured":"Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579\u201383.","journal-title":"Clin Microbiol Infect"},{"key":"1851_CR2","unstructured":"Prendiville W, Sankaranarayana R. Colposcopy and Treatment of Cervical Precancer. IARC Technical Publication No. 45. Lyon, France: International Agency for Research on Cancer. 2017. Available from: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Iarc-Technical-Publications\/Colposcopy-And-Treatment-Of-Cervical-Precancer-2017."},{"issue":"9","key":"1851_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/jnci\/dji115","volume":"97","author":"WA Leyden","year":"2005","unstructured":"Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1851_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3322\/caac.21452","volume":"68","author":"CA Doubeni","year":"2018","unstructured":"Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, et al. Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin. 2018;68(3):199\u2013216.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1851_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00761-020-00757-y","volume":"26","author":"P Hillemanns","year":"2020","unstructured":"Hillemanns P, Iftner T. New secondary prevention of cervical cancer in Germany starting in 2020. Onkologe. 2020;26(7):591\u20137.","journal-title":"Onkologe"},{"issue":"5","key":"1851_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ypmed.2010.08.008","volume":"51","author":"SJ Klug","year":"2010","unstructured":"Klug SJ, Taylor KJ, Scheidemann-Wesp U, Lautz D, Guther B, Potthoff P, et al. Participation in cervical cancer screening in Germany. Prev Med. 2010;51(5):431\u20132.","journal-title":"Prev Med"},{"issue":"7","key":"1851_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253801","volume":"16","author":"LF Tanaka","year":"2021","unstructured":"Tanaka LF, Schriefer D, Radde K, Schauberger G, Klug SJ. Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study. PLoS ONE. 2021;16(7): e0253801.","journal-title":"PLoS ONE"},{"issue":"5","key":"1851_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000331811","volume":"55","author":"K Marquardt","year":"2011","unstructured":"Marquardt K, Buttner HH, Broschewitz U, Barten M, Schneider V. Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause. Acta Cytol. 2011;55(5):433\u20137.","journal-title":"Acta Cytol"},{"issue":"6","key":"1851_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2303.2008.00623.x","volume":"19","author":"J Jordan","year":"2008","unstructured":"Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008;19(6):342\u201354.","journal-title":"Cytopathology"},{"issue":"2","key":"1851_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ygyno.2020.08.033","volume":"159","author":"R Landy","year":"2020","unstructured":"Landy R, Mathews C, Robertson M, Wiggins CL, McDonald YJ, Goldberg DW, et al. A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. Gynecol Oncol. 2020;159(2):344\u201353.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1851_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ypmed.2007.06.007","volume":"45","author":"AR Spence","year":"2007","unstructured":"Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45(2):93\u2013106.","journal-title":"Prev Med"},{"issue":"4","key":"1851_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3747\/co.22.2575","volume":"22","author":"J Murphy","year":"2015","unstructured":"Murphy J, Varela NP, Elit L, Lytwyn A, Yudin M, Shier M, et al. The organization of colposcopy services in Ontario: recommended framework. Curr Oncol. 2015;22(4):287\u201396.","journal-title":"Curr Oncol"},{"issue":"4","key":"1851_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CEJ.0000000000000173","volume":"25","author":"C Campari","year":"2016","unstructured":"Campari C, Fedato C, Iossa A, Petrelli A, Zorzi M, Anghinoni E, et al. Cervical cancer screening in immigrant women in Italy: a survey on participation, cytology and histology results. Eur J Cancer Prev. 2016;25(4):321\u20138.","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"1851_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12905-020-01161-9","volume":"21","author":"T Carrillo","year":"2021","unstructured":"Carrillo T, Montealegre JR, Bracamontes CG, Scheurer ME, Follen M, Mulla ZD. Predictors of timely diagnostic follow-up after an abnormal Pap test among Hispanic women seeking care in El Paso, Texas. BMC Womens Health. 2021;21(1):11.","journal-title":"BMC Womens Health"},{"issue":"6","key":"1851_CR15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jog.12413","volume":"40","author":"R Collier","year":"2014","unstructured":"Collier R, Quinlivan JA. Domestic violence is a leading risk factor in default from colposcopy services. J Obstet Gynaecol Res. 2014;40(6):1785\u201390.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"1851_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/bjc.2015.176","volume":"113","author":"E Douglas","year":"2015","unstructured":"Douglas E, Wardle J, Massat NJ, Waller J. Colposcopy attendance and deprivation: a retrospective analysis of 27,193 women in the NHS Cervical Screening Programme. Br J Cancer. 2015;113(1):119\u201322.","journal-title":"Br J Cancer"},{"issue":"1","key":"1851_CR17","first-page":"e22","volume":"58","author":"L Elit","year":"2012","unstructured":"Elit L, Krzyzanowska M, Saskin R, Barbera L, Razzaq A, Lofters A, et al. Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results. Can Fam Physician. 2012;58(1):e22-31.","journal-title":"Can Fam Physician"},{"issue":"8","key":"1851_CR18","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/ijc.33348","volume":"148","author":"LI Green","year":"2021","unstructured":"Green LI, Mathews CS, Waller J, Kitchener H, Rebolj M, Committee THPS. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing. Int J Cancer. 2021;148(8):1850\u20137.","journal-title":"Int J Cancer"},{"issue":"7","key":"1851_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.pec.2017.01.020","volume":"100","author":"SM Miller","year":"2017","unstructured":"Miller SM, Tagai EK, Wen KY, Lee M, Hui SA, Kurtz D, et al. Predictors of adherence to follow-up recommendations after an abnormal Pap smear among underserved inner-city women. Patient Educ Couns. 2017;100(7):1353\u20139.","journal-title":"Patient Educ Couns"},{"issue":"5","key":"1851_CR20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/BF03405143","volume":"95","author":"GS Ogilvie","year":"2004","unstructured":"Ogilvie GS, Shaw EA, Lusk SP, Zazulak J, Kaczorowski JA. Access to colposcopy services for high-risk Canadian women: can we do better? Can J Public Health. 2004;95(5):346\u201351.","journal-title":"Can J Public Health"},{"issue":"2","key":"1851_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ejogrb.2012.08.001","volume":"165","author":"L Sharp","year":"2012","unstructured":"Sharp L, Cotton S, Thornton A, Gray N, Cruickshank M, Whynes D, et al. Who defaults from colposcopy? A multi-centre, population-based, prospective cohort study of predictors of non-attendance for follow-up among women with low-grade abnormal cervical cytology. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):318\u201325.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"1851_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/19325037.2013.838881","volume":"44","author":"LJ Fish","year":"2013","unstructured":"Fish LJ, Moorman PG, Wordlaw-Stintson L, Vidal A, Smith JS, Hoyo C. Factors associated with adherence to follow-up colposcopy. Am J Health Educ. 2013;44(6):293\u20138.","journal-title":"Am J Health Educ"},{"issue":"3","key":"1851_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/jwh.2006.0161","volume":"16","author":"KS Eggleston","year":"2007","unstructured":"Eggleston KS, Coker AL, Das IP, Cordray ST, Luchok KJ. Understanding barriers for adherence to follow-up care for abnormal pap tests. J Womens Health. 2007;16(3):311\u201330.","journal-title":"J Womens Health"},{"issue":"1","key":"1851_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12905-020-01168-2","volume":"21","author":"C Buick","year":"2021","unstructured":"Buick C, Murphy KJ, Howell D, Metcalfe K. Understanding the role of oncogenic human papillomavirus (HPV) status on adherence behaviors among women with abnormal cervical cytology. BMC Womens Health. 2021;21(1):29.","journal-title":"BMC Womens Health"},{"key":"1851_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-6874-11-11","volume":"11","author":"DR Swancutt","year":"2011","unstructured":"Swancutt DR, Greenfield SM, Luesley DM, Wilson S. Women\u2019s experience of colposcopy: a qualitative investigation. BMC Womens Health. 2011;11:11.","journal-title":"BMC Womens Health"},{"issue":"1","key":"1851_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12905-018-0691-0","volume":"18","author":"A Young","year":"2018","unstructured":"Young A, Cotton S, Cruickshank ME. Information needs of young women vaccinated against HPV attending colposcopy: a qualitative study. BMC Womens Health. 2018;18(1):200.","journal-title":"BMC Womens Health"},{"issue":"3","key":"1851_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1055-9965.EPI-20-1003","volume":"30","author":"LA Liang","year":"2021","unstructured":"Liang LA, Einzmann T, Franzen A, Schwarzer K, Schauberger G, Schriefer D, et al. Cervical cancer screening: comparison of conventional Pap smear test, liquid-based cytology, and human papillomavirus testing as stand-alone or cotesting strategies. Cancer Epidemiol Biomark Prev. 2021;30(3):474\u201384.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"1851_CR28","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30146","volume":"139","author":"K Radde","year":"2016","unstructured":"Radde K, Gottschalk A, Bussas U, Sch\u00fclein S, Schriefer D, Seifert U, et al. Invitation to cervical cancer screening does increase participation in Germany: results from the MARZY study. Int J Cancer. 2016;139(5):1018\u201330.","journal-title":"Int J Cancer"},{"key":"1851_CR29","unstructured":"Deutschen Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e. V. (DGGG). Interdisziplin\u00e4re S2k-Leitlinie f\u00fcr die Pr\u00e4vention, Diagnostik und Therapie der HPV-Infektion und pr\u00e4invasiver L\u00e4sionen des weiblichen Genitale. AWMF-Leitlinien-Register. 2008 July 2008. Report No.: AWMF 015\/027. [Accessed on 24 June 2021]. Available from: https:\/\/www.ag-cpc.de\/wp-content\/uploads\/2018\/07\/015-027_S2_IDA_Praevention__Diagnostik_und_Therapie_der_HPV-Infektion_und_praeinvasiver_Laesionen_des_weiblichen_Genitale_06-2008_09-2012.pdf."},{"issue":"10","key":"1851_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/0895-4356(95)00015-V","volume":"48","author":"A Bennetts","year":"1995","unstructured":"Bennetts A, Irwig L, Oldenburg B, Simpson JM, Mock P, Boyes A, et al. PEAPS-Q: a questionnaire to measure the psychosocial effects of having an abnormal pap smear. Psychosocial effects of abnormal Pap smears questionnaire. J Clin Epidemiol. 1995;48(10):1235\u201343.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1851_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ypmed.2004.02.004","volume":"39","author":"E Shinn","year":"2004","unstructured":"Shinn E, Basen-Engquist K, Le T, Hansis-Diarte A, Bostic DS, Martinez-Cross J, et al. Distress after an abnormal Pap smear result: scale development and psychometric validation. Prev Med. 2004;39(2):404\u201312.","journal-title":"Prev Med"},{"key":"1851_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.csda.2013.02.017","author":"M Schomaker","year":"2014","unstructured":"Schomaker M, Heumann C. Model selection and model averaging after multiple imputation. Comput Stat Data Anal. 2014. https:\/\/doi.org\/10.1016\/j.csda.2013.02.017.","journal-title":"Comput Stat Data Anal"},{"issue":"3","key":"1851_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/sj.bjc.6605771","volume":"103","author":"M Rebolj","year":"2010","unstructured":"Rebolj M, Lynge E. Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. Br J Cancer. 2010;103(3):310\u20134.","journal-title":"Br J Cancer"},{"issue":"6","key":"1851_CR34","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/01.AOG.0000159549.56601.75","volume":"105","author":"VB Benard","year":"2005","unstructured":"Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105(6):1323\u20138.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"1851_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1055\/s-0034-1383042","volume":"74","author":"MW Beckmann","year":"2014","unstructured":"Beckmann MW, Quaas J, Bischofberger A, K\u00e4mmerle A, Lux MP, Wesselmann S. Establishment of the certification system \u201cgynaecological dysplasia\u201d in Germany. Geburtshilfe Frauenheilkd. 2014;74(9):860\u20137.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"3","key":"1851_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4236\/ojpm.2014.43017","volume":"4","author":"L Wordlaw-Stinson","year":"2014","unstructured":"Wordlaw-Stinson L, Jones S, Little S, Fish L, Vidal A, Smith JS, et al. Challenges and recommendations to recruiting women who do not adhere to follow-up gynecological care. Open J Prev Med. 2014;4(3):123\u20138.","journal-title":"Open J Prev Med"},{"key":"1851_CR37","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/ijc.32540","volume":"146","author":"E McBride","year":"2020","unstructured":"McBride E, Marlow LAV, Forster AS, Ridout D, Kitchener H, Patnick J, et al. Anxiety and distress following receipt of results from routine HPV primary testing in cervical screening: the psychological impact of primary screening (PIPS) study. Int J Cancer. 2020;146:2113\u201321.","journal-title":"Int J Cancer"},{"issue":"8","key":"1851_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.1471-0528.2011.02996.x","volume":"118","author":"R de Bie","year":"2011","unstructured":"de Bie R, Massuger L, Lenselink C, Derksen Y, Prins J, Bekkers R. The role of individually targeted information to reduce anxiety before colposcopy: a randomised controlled trial. BJOG. 2011;118(8):945\u201350.","journal-title":"BJOG"},{"key":"1851_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ypmed.2018.08.017","volume":"115","author":"M O'Connor","year":"2018","unstructured":"O\u2019Connor M, O\u2019Leary E, Waller J, Gallagher P, Martin CM, O\u2019Leary JJ, et al. Socio-economic variations in anticipated adverse reactions to testing HPV positive: implications for the introduction of primary HPV-based cervical screening. Prev Med. 2018;115:90\u20136.","journal-title":"Prev Med"},{"key":"1851_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4823","volume":"363","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363: k4823.","journal-title":"BMJ"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01851-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01851-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T07:03:22Z","timestamp":1657350202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01851-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1851"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01851-6","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,9]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent to participate in the MARZY prospective cohort study was provided in written form by all study participants prior to screening at study baseline. The MARZY study was approved by the ethical committee of the state of Rhineland-Palatinate (Landes\u00e4rztekammer Rheinland-Pfalz: 837.438.03 (4100)) and the state government data protection office. All recruitment, data collection and analyses were performed in accordance to Good Epidemiological Practice guidelines and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable (NA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HI reports co-ownership of a laboratory for cytology and molecular diagnostics. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}